Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.26 USD
Change Today +0.02 / 0.32%
Volume 2.4M
SPPI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 4:30 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

11500 South Eastern Avenue

Suite 240

Henderson, NV 89052

United States

Phone: 702-835-6300

Fax: 702-260-7405

Spectrum Pharmaceuticals, Inc., together with its wholly-owned subsidiaries, operates as a biotechnology company with integrated commercial and drug development operations with a primary focus in hematology and oncology. The company markets four oncology drugs, such as FUSILEV injection for patients in the U.S. with advanced metastatic colorectal cancer and to counteract certain side effects of methotrexate therapy; ZEVALIN injection for patients in the U.S. and various international markets with follicular non-Hodgkin’s lymphoma (NHL); FOLOTYN injection for patients in the U.S. with relapsed or refractory peripheral T-cell lymphoma (PTCL); and MARQIBO injection for patients in the U.S. with relapsed Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). Product Portfolio The company has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. Commercialized Products FUSILEV FUSILEV (levoleucovorin) is a novel folate analog formulation and the pharmacologically active isomer (the levo-isomer) of the racemic compound, calcium leucovorin. FUSILEV is approved as a ready-to-use solution and as freeze-dried powder. FUSILEV has various indications for use, such as in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer; for rescue after high-dose methotrexate therapy in osteosarcoma; and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. The product similar to FUSILEV is marketed outside the U.S. by Pfizer, Inc.; Sanofi-Aventis, Inc.; and Takeda. FOLOTYN FOLOTYN (pralatrexate injection) is a folate analogue metabolic inhibitor that is discovered by Memorial Sloan-Kettering Cancer Center, SRI International, and Southern Research Institute; and developed by Allos Therapeutics, Inc. The U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory PTCL. FOLOTYN is the first chemotherapy approved by the FDA for the treatment of relapsed or refractory PTCL and has been available to patients in the U.S. The company is exploring additional settings for FOLOTYN where methotrexate, a drug in the same category as FOLOTYN, has been used for decades in the treatment of breast cancer, bladder cancer, and lung cancer. ZEVALIN ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a prescription medication that is part of a three step treatment regimen consisting of two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN. Rituximab is used to reduce the number of B-cells in the blood and Y-90 ZEVALIN is then given to treat NHL. It is approved in the U.S. and approximately 40 countries outside the U.S., including countries in Europe, Latin America, and Asia for the treatment of patients with recurring, low-grade or follicular B-cell NHL, after other anticancer drugs are no longer working; and newly diagnosed follicular NHL following a response to initial anticancer therapy. The company is working towards a new indication for ZEVALIN for diffuse large B-cell lymphoma. ZEVALIN would be used as an add-on to frontline therapy. Various Phase 2 studies have been completed by investigators with high response rates in this indication. The company intends to complete its Phase 3 study enrollment in 2016 and file a supplemental Biologics License Application in 2018. MARQIBO MARQIBO is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. MARQIBO’s approved indication is for the treatment of adult patients with Philadelphia chromosome-negative ALL in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. MARQIBO is also being explored for the treatment of the ALL indication, as well as in NHL in addition to its approved treatment for Philadelphia chromosome-negative ALL. During 2014, the company also planned to conduct an

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPPI:US $6.26 USD +0.02

SPPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.65 USD -0.07
GlaxoSmithKline SAE £12.00 EGP 0.00
Progenics Pharmaceuticals Inc $6.95 USD +0.13
Rigel Pharmaceuticals Inc $3.56 USD +0.26
Wyeth Ltd 1,334 INR 0.00
View Industry Companies
 

Industry Analysis

SPPI

Industry Average

Valuation SPPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRUM PHARMACEUTICALS INC, please visit www.sppirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.